Alvotech
ALVOHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 28
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. With a market capitalization of $1.07B, it sits in small-cap territory. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Market Cap
$1.07B
Beta
0.21
P/E (TTM)
34.30
P/E (Fwd)
19.17
EPS (TTM)
$0.10
EPS (Fwd)
$0.18
ROE
—
ROA
3.8%
Cash
$63.8M
Total Debt
$1.46B
Free CF
-$150.9M
52W Change
-70.0%
Annual Financials
Cash vs Debt
Alvotech carries $1.46B in total debt against $63.8M in cash reserves — debt is roughly 22.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$150.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROA of 3.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $83.0M (2022) to $586.3M (2025), reflecting a 606% increase over the period.
With a beta below 0.7, Alvotech typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Alvotech's trajectory.